异麦芽糖酐铁治疗缺铁性贫血合并全血细胞减少的疗效及安全性分析

Efficacy and safety of iron isomaltoside in treatment of iron deficiency anemia with pancytopenia

目的 本文探讨了异麦芽糖酐铁(Iron Isomaltoside, IIM)在缺铁性贫血(iron deficiency anemia, IDA)中的疗效及安全性。缺铁性贫血合并全血细胞减少的要重视。方法 回顾性分析2021年4月1日至2023年3月1日河南省肿瘤医院20例接受IIM治疗IDA合并全血细胞减少的患者。结果 20例患者应用IIM后均有效,无1例死亡,脱离红细胞输注中位时间为3(1~7)d, 1月后血红蛋白均明显恢复50%以上。IIM治疗后1周,血液学反应率为100%;治疗后1个月,血液学反应率仍为100%。结论 异麦芽糖酐铁可安全有效地帮助IDA患者更快地提升血红蛋白和铁蛋白水平,并且改善骨髓造血功能。

Objective To investigate the efficacy and safety of iron isomaltoside(IIM)in iron deficiency anemia(IDA).Attention should be paid to iron deficiency anemia combined with pancytopenia.Methods A retrospective analysis was conducted on 20 patients with IDA and pancytopenia who received IIM treatment at Henan Cancer Hospital from April 1,2021 to March 1,2023.Results All 20 patients were effective after IIM treatment and none of them suffered from death.The meadia time of RBC-transfusion independence was 3(1-7)days.All of patients had response after IM therapy.The hemoglobin significantly increased to more than 50%comparing with baseline,which had persistent response with 100%after one month treatment.Conclusion After treatment with Iron isomaltoside,patient can safely and effectively improve the hemoglobin and ferritin level of IDA patients,and improve the hematopoietic function of bone marrow.